Results
In vitro, treatment of gastric cancer cells with 20-80 nM BEZ235 decreased cell growth in a dose-dependent manner in all cell lines tested (up to −70%). This antiproliferative activity was linked with a G 1 cell cycle arrest (up to 75%). No significant induction of apoptosis by BEZ235 was observed. On the molecular level, BEZ235 led to a decrease of phosphorylation of AKT and S6 protein. In vivo, treatment with 20 and 40 mg/kg BEZ235 resulted in a significant anti-tumor effect in a N87 gastric cancer xenograft mouse model. BEZ235 therapy had no anti-tumort effect on MKN45 xenografts despite similar potent PI3K/mTOR target inhibition by BEZ235 in both xenograft models. However, expression of the proliferation marker thymidinthymidine kinase 1 correlated with sensitivity to BEZ235 in vivo. In line, [ 18 F]FLT uptake was significantly reduced only in the BEZ235-sensitive tumor xenograft model as measured by small animal PET.
Conclusions
In conclusion, our study shows that dual PI3K/mTOR inhibition by BEZ235 is a valuable target for gastric cancer therapy but is tumor model-dependent. Correlative studies with implementation of non-invasive imaging tools such as [
18 F]FLT PET might be a novel and promising strategy for optimizing clinical testing of dual PI3K/mTOR inhibitors.
